Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
Conditions
Interventions
Venetoclax
Rovalpituzumab Tesirine
+1 more
Locations
26
United States
Moores Cancer Center at UC San Diego /ID# 157374
La Jolla, California, United States
The University of Chicago Medical Center /ID# 157375
Chicago, Illinois, United States
Carolina BioOncology Institute /ID# 157376
Huntersville, North Carolina, United States
South Texas Accelerated Research Therapeutics /ID# 157378
San Antonio, Texas, United States
Virginia Cancer Specialists - Fairfax /ID# 157377
Fairfax, Virginia, United States
Blacktown Hospital /ID# 167386
Blacktown, New South Wales, Australia
Start Date
December 14, 2016
Primary Completion Date
March 29, 2022
Completion Date
March 29, 2022
Last Updated
April 14, 2022
NCT07177937
NCT07387068
NCT07360314
NCT07539285
NCT07403721
NCT07524348
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions